Furthermore, the complement and coagulation cascade pathway, which is upregulated in the high-risk group, has been reported to play an immunosuppressive function in TME, which may be associated with the suppression of anti-tumor CD8+ T cell responses (Holers, 2014). The gene discussed is CD8A; the disease is neoplasm.